Last reviewed 2026-05-15 · How we verify

Cohort 2: JMKX003142 and rifampicin

Jemincare · Phase 1 active Small molecule

Cohort 2: JMKX003142 and rifampicin is a Small molecule drug developed by Jemincare. It is currently in Phase 1 development.

At a glance

Generic name	Cohort 2: JMKX003142 and rifampicin
Sponsor	Jemincare
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort 2: JMKX003142 and rifampicin CI brief — competitive landscape report
Cohort 2: JMKX003142 and rifampicin updates RSS · CI watch RSS
Jemincare portfolio CI

Frequently asked questions about Cohort 2: JMKX003142 and rifampicin

What is Cohort 2: JMKX003142 and rifampicin?

Cohort 2: JMKX003142 and rifampicin is a Small molecule drug developed by Jemincare.

Who makes Cohort 2: JMKX003142 and rifampicin?

Cohort 2: JMKX003142 and rifampicin is developed by Jemincare (see full Jemincare pipeline at /company/jemincare).

What development phase is Cohort 2: JMKX003142 and rifampicin in?

Cohort 2: JMKX003142 and rifampicin is in Phase 1.

Manufacturer: Jemincare — full pipeline
Compare: Cohort 2: JMKX003142 and rifampicin vs similar drugs
Pricing: Cohort 2: JMKX003142 and rifampicin cost, discount & access